Regulations.gov document
Considerations for the Use of Human and Animal-Derived Materials and Components in the…
Notice · FDA-2024-D-1244 · posted Apr 30, 2024
Key facts
| Document ID | FDA-2024-D-1244-0001 |
|---|---|
| Title | Considerations for the Use of Human and Animal-Derived Materials and Components in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products; Draft Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2024-D-1244 |
| Posted | Apr 30, 2024 |
| Federal Register citation | 89 FR 34253 |
| FR document number | 2024-09286 |
| Effective date | Apr 30, 2024 |
At a glance
- 1–9 Pages
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: